Anebulo Pharmaceuticals (ANEB) Competitors $1.07 +0.06 (+5.93%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANEB vs. PRQR, HURA, DMAC, ACIU, IKT, ESPR, DERM, NBTX, FDMT, and ENGNShould you be buying Anebulo Pharmaceuticals stock or one of its competitors? The main competitors of Anebulo Pharmaceuticals include ProQR Therapeutics (PRQR), TuHURA Biosciences (HURA), DiaMedica Therapeutics (DMAC), AC Immune (ACIU), Inhibikase Therapeutics (IKT), Esperion Therapeutics (ESPR), Journey Medical (DERM), Nanobiotix (NBTX), 4D Molecular Therapeutics (FDMT), and enGene (ENGN). These companies are all part of the "pharmaceutical products" industry. Anebulo Pharmaceuticals vs. ProQR Therapeutics TuHURA Biosciences DiaMedica Therapeutics AC Immune Inhibikase Therapeutics Esperion Therapeutics Journey Medical Nanobiotix 4D Molecular Therapeutics enGene Anebulo Pharmaceuticals (NASDAQ:ANEB) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership. Is ANEB or PRQR more profitable? Anebulo Pharmaceuticals has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -134.31%. ProQR Therapeutics' return on equity of -71.58% beat Anebulo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Anebulo PharmaceuticalsN/A -119.54% -108.08% ProQR Therapeutics -134.31%-71.58%-19.70% Which has more risk & volatility, ANEB or PRQR? Anebulo Pharmaceuticals has a beta of -1.12, indicating that its share price is 212% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Do institutionals & insiders believe in ANEB or PRQR? 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor ANEB or PRQR? In the previous week, ProQR Therapeutics had 3 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 6 mentions for ProQR Therapeutics and 3 mentions for Anebulo Pharmaceuticals. Anebulo Pharmaceuticals' average media sentiment score of 0.33 beat ProQR Therapeutics' score of -0.01 indicating that Anebulo Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anebulo Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ProQR Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, ANEB or PRQR? Anebulo Pharmaceuticals has higher earnings, but lower revenue than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnebulo PharmaceuticalsN/AN/A-$8.20M-$0.26-3.89ProQR Therapeutics$18.97M9.76-$30.43M-$0.35-5.03 Do analysts rate ANEB or PRQR? Anebulo Pharmaceuticals currently has a consensus price target of $5.50, suggesting a potential upside of 444.50%. ProQR Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 354.55%. Given Anebulo Pharmaceuticals' higher probable upside, analysts plainly believe Anebulo Pharmaceuticals is more favorable than ProQR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the MarketBeat Community prefer ANEB or PRQR? ProQR Therapeutics received 329 more outperform votes than Anebulo Pharmaceuticals when rated by MarketBeat users. However, 90.91% of users gave Anebulo Pharmaceuticals an outperform vote while only 62.20% of users gave ProQR Therapeutics an outperform vote. CompanyUnderperformOutperformAnebulo PharmaceuticalsOutperform Votes1090.91% Underperform Votes19.09%ProQR TherapeuticsOutperform Votes33962.20% Underperform Votes20637.80% SummaryProQR Therapeutics beats Anebulo Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Get Anebulo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANEB vs. The Competition Export to ExcelMetricAnebulo PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.50M$6.55B$5.42B$8.48BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-3.619.1426.8320.05Price / SalesN/A255.59393.86117.02Price / CashN/A65.8538.2534.62Price / Book6.736.546.874.61Net Income-$8.20M$143.51M$3.22B$248.19M7 Day Performance3.59%4.66%5.65%2.88%1 Month Performance0.01%10.63%13.54%15.40%1 Year Performance-53.02%-1.05%18.16%7.68% Anebulo Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANEBAnebulo Pharmaceuticals2.585 of 5 stars$1.07+5.9%$5.50+414.0%-53.0%$43.96MN/A-3.824Gap DownPRQRProQR Therapeutics3.0806 of 5 stars$1.59-1.2%$8.75+450.3%-8.3%$167.29M$18.91M-4.97180HURATuHURA BiosciencesN/A$3.82-4.3%$12.67+231.6%N/A$166.86MN/A0.00N/ANews CoverageEarnings ReportAnalyst RevisionDMACDiaMedica Therapeutics1.5038 of 5 stars$3.83+4.6%$8.00+108.9%+35.3%$164.14MN/A-6.8420News CoverageAnalyst RevisionGap UpACIUAC Immune2.7825 of 5 stars$1.63-3.0%$10.00+513.5%-44.6%$163.67M$28.30M-3.54140Positive NewsGap UpIKTInhibikase Therapeutics1.5308 of 5 stars$2.19+9.5%$6.50+196.8%+7.0%$162.81M$260,000.00-0.826News CoverageESPREsperion Therapeutics3.6036 of 5 stars$0.80+0.1%$6.25+682.3%-63.4%$158.30M$259.57M-1.25200High Trading VolumeDERMJourney Medical2.1612 of 5 stars$6.83-0.7%$9.88+44.6%+102.4%$157.80M$56.13M-7.2790News CoverageEarnings ReportAnalyst RevisionNBTXNanobiotix1.7289 of 5 stars$3.33-2.3%$8.00+140.2%-46.1%$156.95M$-11,609,000.000.00100FDMT4D Molecular Therapeutics2.9487 of 5 stars$3.32+7.8%$29.56+790.2%-85.2%$153.80M$37,000.00-1.16120Gap UpENGNenGene2.9139 of 5 stars$2.97+0.3%$23.29+684.0%-66.9%$151.40MN/A-5.1231Positive News Related Companies and Tools Related Companies ProQR Therapeutics Alternatives TuHURA Biosciences Alternatives DiaMedica Therapeutics Alternatives AC Immune Alternatives Inhibikase Therapeutics Alternatives Esperion Therapeutics Alternatives Journey Medical Alternatives Nanobiotix Alternatives 4D Molecular Therapeutics Alternatives enGene Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANEB) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anebulo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
